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Ischemic Stroke in Adults With Congenital Heart Disease: A
Population-Based Cohort Study
Mette Glavind B€ulow Pedersen, MD; Morten S. Olsen, MD, PhD; Morten Schmidt, MD, PhD; Søren P. Johnsen, MD, PhD; Christopher Learn,
MD; Henning B. Laursen, MD, DMSc; Nicolas L. Madsen, MD, MPH
Background-—Congenital heart disease (CHD) is associated with risk factors for ischemic stroke including cardiac arrhythmias and
heart failure. However, few long-term follow-up data exist on ischemic stroke risk and associated mortality in adults with CHD.
Methods and Results-—Using Danish nationwide registries, we identified individuals aged ≥18 years diagnosed with CHD, at any
age, from 1963 to 2017 and a sex and birth year-matched (1:10) general population comparison cohort. We computed risks, as
well as sex and birth year-adjusted hazard ratios (aHRs) for ischemic stroke and 30-day post-stroke mortality in CHD adults
compared with the general population. Analyses were stratified according to age <60 years (young) and ≥60 years (older). We
identified 16 836 adults with CHD. The risk of ischemic stroke at age 60 years was 7.4% in the CHD cohort and 2.9% in the general
population cohort. The adjusted hazard ratios for ischemic stroke compared with the general population was 3.8 (95% CI: 3.3–4.3)
in young CHD adults and 1.6 (95% CI: 1.4–1.9) in older CHD adults. The adjusted hazard ratios for post-stroke mortality compared
with the general population was 2.3 (95% CI: 1.2–4.4) in young CHD adults and 1.3 (95% CI: 0.9–1.9) in older CHD adults.
Conclusions-—Both younger and older CHD adults have an increased risk of ischemic stroke and by 60 years of age 7.4% of CHD
adults will have had an ischemic stroke. Post-stroke mortality was also increased in CHD adults compared with the general
population. ( J Am Heart Assoc. 2019;8:e011870. DOI: 10.1161/JAHA.118.011870.)
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T he prevalence of adults living with a congenital heartdisease (CHD) is increasing, resulting in a greater need
to research the long-term prognosis of this patient group.1
Risk of ischemic stroke is one such outcome in need of
additional discovery. Adults with CHD are at greater risk of
cardiac arrhythmias and congestive heart failure,2,3 both well
described risk factors for ischemic stroke in the general
population.4,5 Heart surgery with implantation of mechanical
heart valves is another risk factor for ischemic stroke in the
adult CHD population.6,7
A previous study investigated the risk of ischemic stroke in
CHD children and young adults compared with a general
population cohort, however, data on ischemic stroke risk
among older patients with CHD are limited.8,9 Additionally,
CHD is a heterogeneous disease with varying comorbidities.
Thus, identifying subgroups of CHD adults at particular high
risk of ischemic stroke is of clinical relevance.10
We therefore estimated the risk of ischemic stroke in the adult
CHD population in Denmark compared with the general popula-
tion, overall and according to CHD-related risk factors. Moreover,
we estimated the incidence of ischemic stroke in the adult CHD
population in relation to CHA2DS2VASc scores and evaluated the
use of antithrombotic therapy in the adult CHD population. Finally,
we compared 30-day post-stroke mortality in the adult CHD
population with that of the general population cohort.
Methods
Setting
Our study was conducted within the entire Danish population
of 5.7 million individuals. All Danish citizens are provided
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tax-supported health care through the Danish National Health
Service, which encompasses universal and free access to
both hospital care and primary health care, including care for
CHD and ischemic stroke. No informed written consent or
permission from the Scientific Ethical Committee is required
for register-based studies in Denmark. The data will not be
made available to other researchers for purpose of reproduc-
ing the results as that would be a violation of the Danish
General Data Protection Regulation. Analytic methods are
described below.
Data Linkage
Since 1968, the Central Office of Civil Registration has
assigned all residents in Denmark a unique 10-digit civil
personal registration number, which is used to track residents
across all Danish registries.11 This system allowed for unam-
biguous individual-level linkage of data from all sources used in
this study and provided us with virtually complete follow-up for
death, emigration, and the outcome under study.11
Study Population
Congenital heart disease cohort
We identified all Danish individuals diagnosed with CHD
during 2 separate periods. As described previously, we used
medical record reviews12 to identify patients diagnosed in the
period 1963 to 1974 and the DNPR (Danish National Patient
Registry) to identify those diagnosed between 1977 and
2017. Individuals exclusively diagnosed with CHD between
1974 and 1977 were not captured in this study. The DNPR
contains information on all hospital admissions in Denmark
and includes individuals’ civil personal registration numbers,
dates of admission and discharge, surgical procedures, one
primary diagnosis per hospital admission and additional
relevant secondary diagnoses, coded by physicians according
to the International Classification of Diseases (ICD)13. The
Eighth Revision of the ICD was used until the end of 1993 and
the Tenth Revision thereafter.
We categorized CHD severity into broad categories: mild to
moderate, severe, and unclassified complexity.14–16 Mild and
moderate CHD types were exclusively of biventricular phys-
iology and included lesions commonly classified as simple
(including atrial and ventricular septal defects, coarctation,
patent ductus arteriosus, and isolated pulmonic stenosis).
Mild and moderate types were separate according to proce-
dural intervention history such that those classified as mild
had no history of cardiothoracic surgical or procedural history.
Severe CHD was classified as complex biventricular physiol-
ogy (including tetralogy of Fallot, pulmonary atresia, atrioven-
tricular septal defects, transposition of the great arteries), or a
history of single-ventricle diagnoses or palliative surgery such
as Norwood, Glenn, and Fontan. The category of unclassified
complexity included only those diagnoses that could not
readily be assigned a severity category.
Work-up after an ischemic stroke may, in the optimal
setting, include an echocardiography that may unmask an
asymptomatic CHD, such as a small atrial septal defect, that
would otherwise gone unnoticed. To avoid overestimating the
risk of ischemic stroke in CHD adults we excluded individuals
who were registered with both CHD and an ischemic stroke
diagnosis within the same 12-month period (n=183).
General population comparison cohort
We used the Civil Registration System11 to identify a general
population comparison cohort. We matched on sex and birth
year at a ratio of 10 general population individuals without a
CHD per 1 CHD adult. If an individual from the general
population cohort was diagnosed with CHD during follow-up
this individual would move to the CHD cohort and be matched
with 10 general population individuals.
Outcomes
Ischemic stroke and post-ischemic stroke mortality
Within the CHD cohort and the general population comparison
cohort, we identified patients with a primary discharge
diagnosis of first-time ischemic stroke in the DNPR
(Table S1). We defined post-stroke mortality as death within
30 days of a first-time ischemic stroke diagnosis in the DNPR.
Clinical Perspective
What Is New?
• In this nationwide population-based cohort study of 16 836
congenital heart disease (CHD) adults, the lifelong risk and
mortality of ischemic stroke was elevated compared with a
sex- and birth year-matched comparison cohort, especially
in those aged <60 years.
• Traditional stroke risk factors ie, heart failure, atrial
arrythmia, and mechanical heart valve replacement further
increased this risk, despite the indication of a high
prevalence of anticoagulation therapy use in CHD adults.
• In CHD adults a CHA2DS2VASc score of ≥1 indicated a
higher risk of ischemic stroke compared with a score of 0.
What Are the Clinical Implications?
• The lifelong increased risk of ischemic stroke and increased
ischemic stroke mortality in CHD adults triggers a need for
targeted and timely intervention by clinicians to identify
those at highest risk.
• The CHA2DS2VASc score could be a usable supplemental
tool in identifying CHD adults at risk of ischemic stroke.
DOI: 10.1161/JAHA.118.011870 Journal of the American Heart Association 2
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Antithrombotic therapy
We obtained data on the use of antithrombotic therapy from
the National Prescription Registry.17 This database provides
detailed information on all redeemed drug prescriptions
dispensed from all Danish pharmacies and is complete since
1995. We used Anatomical Therapeutic Chemical Classifica-
tion codes to identify antithrombotic medications (Table S1).
We grouped the medications into the following categories:
Vitamin K antagonists, non-vitamin K oral antagonists and
platelet aggregation inhibitors. Use of antithrombotic therapy
was assessed as the number of filled prescriptions between
January 1, 2015 until December 31, 2016 in CHD cohort
adults and general population comparison cohort members
that were alive on December 31, 2016.
Covariables
CHA2DS2VASc score
To establish the CHA2DS2VASc score
18 of CHD adults during
the time of follow up, we identified dates of first-time diagnoses
of congestive heart failure, hypertension, diabetes mellitus,
thromboembolism, hemorrhagic stroke, and vascular disease in
the DNPR. We defined thromboembolic disease as a diagnosis
of prior transitory ischemic attack or systemic embolism
(Table S1). Prior ischemic stroke was not included in the score
because the study outcome was first-time ischemic stroke. We
defined vascular disease as a diagnosis of myocardial infarc-
tion, atherosclerosis or history of a previous coronary bypass
operation, coronary thrombendarteriectomy, recanalization of
the coronary artery or reconstruction of the coronary artery but
not reconstruction of an anomalous coronary artery (Table S1).
Based on these covariate definitions, individuals were assigned
one point for congestive heart failure, hypertension, age 65 to
74 years, diabetes mellitus, and vascular disease. One point
was assigned for female sex, but only in presence of ≥1 of the
other covariates. Two points were given for age ≥75 years and
previous thromboembolic disease. We defined CHA2DS2VASc
score categories as 0, 1, and ≥2 points.19
Mechanical heart valves
We obtained data on the presence of mechanical heart valves
in the aortic or mitral position from the DNPR. Surgical
procedural codes are presented in Table S1.
Statistical Analysis
Longitudinal follow-up was determined according to the same
design between the CHD cohort and general population
comparison cohort. Specifically, follow-up started either from
the age of 18 years, date of CHD diagnosis (index date for
matched general population comparison cohort members) or
initiation of the DNPR in 1977, whichever came last. Follow up
for both the CHD cohort and general population comparison
cohort ended on date of first diagnosis of ischemic stroke,
death, emigration or end of study (January 1, 2017). There
were 183 CHD individuals excluded from the study because
they had a registered CHD diagnosis and ischemic stroke
diagnosis within the same 12-month period. To address
stroke risk relative to age, we stratified the analyses
according to age <60 years (young) or ≥60 years (older). As
an estimate of absolute risk, we computed cumulative
incidences of ischemic stroke for the adult CHD cohort, as
well as the general population cohort using the method of
Fine and Gray20 to account for death as a competing risk.
We estimated median age at stroke diagnosis in the CHD
cohort and the general population comparison cohort. We
computed overall incidence rates of ischemic stroke, as well
as incidence rates of ischemic stroke according to the
presence of congestive heart failure, atrial fibrillation (AFib),
and mechanical heart valves.
We used Cox proportional hazards regression analysis to
compute sex and birth year adjusted hazard ratios (aHRs) as
estimates of the relative risk of ischemic stroke in adults with
CHD compared with the general population. In a sensitivity
analysis, we excluded the “unspecific stroke” diagnosis code
(ICD-10: I64) from the stroke definition. In subgroup analyses,
we computed aHRs of ischemic stroke in CHD adults with
congestive heart failure, AFib and mechanical heart valves,
respectively, compared with their sex- and birth year-matched
members of the general population comparison cohort. In these
subgroup analyses follow-up started on the date of diagnosis for
congestive heart failure, or AFib, or on date of mechanical heart
valve operation. A corresponding index date for matched
general population comparison cohort members was selected to
determine the initiation of the time to event analysis period.
We scored CHD adults according to the presence of
CHA2DS2VASc score covariates (0, 1, and ≥2), and computed
incidence rates of ischemic stroke in each score category and
hazard ratios (HRs) comparing risk of ischemic stroke of CHD
cohort adults with CHA2DS2VASc scores of 1 or ≥2, respec-
tively, with that of CHD cohort adults with a score of 0. Scores
were included in the Cox models as time-varying covariates.
Furthermore, 30-day post-stoke mortality was assessed
using the Kaplan Meier estimator. We computed aHRs of 30-
day post-stroke mortality in the CHD cohort compared with
the general population cohort according to age categories. We
checked assumptions of proportional hazards graphically.
Finally, we assessed the prevalence of filled antithrombotic
therapy prescriptions during 2015 to 2016 in CHD cohort
adults and general population comparison cohort members
that were alive on December 31, 2016. All analyses were
performed using STATA 14 (StataCorp LP, College Station,
Texas).
DOI: 10.1161/JAHA.118.011870 Journal of the American Heart Association 3
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Results
We identified 16 836 CHD adults, 49% male, diagnosed
between 1963 and 2017 that were alive and living in Denmark
at the age of 18 years. We identified 168 360 general
population individuals (Table 1).
During the follow-up period, 522 CHD adults and 3039
individuals from the general population cohort received an
ischemic stroke diagnosis. Median age at ischemic stroke
diagnosis was 53 years (interquartile range: 40–67) in the
CHD cohort and 69 years (interquartile range: 55–78) in the
general population comparison cohort. The risk of ischemic
stroke by age 30 years was 0.7% (95% CI: 0.6%–0.9%) in the
CHD cohort and 0.1% (95% CI: 0.1%–0.1%) in the general
population comparison cohort. By 60 years of age, the risk of
ischemic stroke was 7.4% (95% CI: 6.6%–8.3%) in the CHD
cohort and 2.9% (95% CI: 2.7%–3.1%) in the general population
comparison cohort (Figure 1).
In the young age category, the overall incidence rate of
ischemic stroke was 1.5 per 1000 person-years for CHD
adults and 0.4 per 1000 person-years in the general
population comparison cohort. In the older age category,
the incidence rate of ischemic stroke was 10.2 per 1000
person-years for CHD adults and 7.2 per 1000 person-years in
the general population. The overall aHR for ischemic stroke in
CHD adults compared with the general population comparison
cohort were 3.8 (95% CI: 3.3–4.3) in the young category and
1.6 (95% CI: 1.4–1.9) in the older category. Excluding the ICD
diagnosis of “unspecified stroke” left the aHR unchanged
(young: 3.8, 95% CI: 3.3–4.5 and older: 1.6, 95% CI: 1.3–1.9).
The aHRs of ischemic stroke according to CHD severity
categories are presented in Table 2.
In subgroup analyses, comparing CHD adults with AFib, or
congestive heart, or a mechanical heart valve to their sex- and
birth year-matched controls, we found increased aHRs of
ischemic stroke in both the young and older categories
(Table 2).
In the CHD cohort, we found increasing incidence of
ischemic stroke with increasing CHA2DS2VASc-scores
(Table 3). The HR comparing ischemic stroke risk among those
Table 1. Characteristics of 16 836 Congenital Heart Disease
Adults and 168 360 General Population Adults Diagnosed in





n (%) n (%)
All 16 836 (100) 168 360 (100)
Male sex 8207 (49) 82 070 (49)
Birth, y
1910 to 1939 1356 (8) 13 560 (8)
1940 to 1959 2704 (16) 27 040 (16)
1960 to 1982 6279 (37) 62 790 (37)
1983 to 1998 6497 (39) 64 970 (39)
CHD severity
Mild/moderate 10 332 (61) . . .
Severe 4247 (25) . . .
Severity not classified 2257 (13) . . .
Age at first CHD diagnosis
0 to 10 y 9942 (59) . . .
>10 y 6894 (41) . . .
Major CHD diagnoses
Atrial septal defect 3568 (21) . . .
Ventricular septal defect 3946 (23) . . .
Patent ductus arteriosus 1534 (9) . . .
Truncus arteriosus 76 (<1) . . .
Coarctation of the aorta 971 (6) . . .
Tetralogy of fallot 626 (4) . . .
Transposition of the
great arteries
363 (2) . . .
Other* 5828 (35) . . .
Comorbidity
Atrial fibrillation 2066 (12) 4765 (3)
Chronic heart failure 1945 (12) 3403 (2)
Mechanical heart valve 455 (3) 100 (<1)
CHD indicates congenital heart disease; mild to moderate, simple biventricular with and
without history of surgical intervention; severe, complex biventricular physiology, history
of single-ventricle diagnoses, or palliative surgery such as Norwood, Glenn, and Fontan.
*All other CHD subtypes such as hypoplastic heart syndrome, tricuspid atresia, and
atrioventricular canal defect, as well as all unclassifiable subtypes.
Figure 1. Cumulative incidence of ischemic stroke with death
as competing risk in congenital heart disease adults (n=16 836)
diagnosed in Denmark from 1963 to 2017 and general population
adults (n=168 360).
DOI: 10.1161/JAHA.118.011870 Journal of the American Heart Association 4
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with a score of 1 to those with a score of 0 was 3.7 (95% CI:
2.5–5.4). The HR for those with a score of ≥2 compared with
those with a score of 0 was 4.5 (95% CI: 3.6–5.7).
When we examined 30-day post-ischemic stroke mortality,
we found the following results. In the young category, 30-day
post-stroke mortality was 5% (95% CI: 3%–8%) in the CHD
cohort and 2% (95% CI: 2%–3%) in the general population
comparison cohort (Figure 2). In the older category, 30-day
post-stroke mortality was 15% (95% CI: 11%–21%) in the CHD
cohort and 13% (95% CI: 11%–14%) in the general population
comparison cohort (Figure 2). The corresponding aHRs of
dying within 30 days of an ischemic stroke were 2.3 (95% CI:
1.2–4.4) in the young category and 1.3 (95% CI: 0.9–1.9) in
the older category.
Analysis of antithrombotic therapy demonstrated that as of
December 31, 2016, 14 259 CHD adults and 151 000
general population comparison cohort members were alive.
Table 4 shows the proportions of CHD adults and general
population comparison cohort members that had filled 1 to 4
prescriptions or ≥5 prescriptions of vitamin K antagonists,
non-vitamin K oral antagonists, and platelet aggregation
inhibitors between January 1, 2015 and December 31, 2016.
The prevalence of filled prescriptions was greater in the CHD
cohort for all 3 medication categories.
Discussion
We found an increased relative risk of ischemic stroke among
CHD adults compared with the general population. The relative
risk increase was particularly high among younger adults,
representative of both increased risk and the low stroke
incidence in the young adult general population. Having a
mechanical heart valve implant was associated with a higher
relative risk of ischemic stroke in young adults with CHD, as was
a diagnosis of heart failure and atrial fibrillation. In addition, a
CHA2DS2VASc score greater than zero was associated with an
increased risk of ischemic stroke in the CHD population. Finally,
we found an increased risk of dying within 30 days of a first-
time ischemic stroke in the CHD cohort, compared with the
general population, regardless of age.
Table 2. Incidence Rates and Adjusted Hazard Ratios of Stroke in Congenital Heart Disease Adults Compared With the General
Population
Young Category Older Category
Incidence Rate* (95% CI)
Adjusted HR† (95% CI)
Incidence Rate* (95% CI)









Overall 1.5 (1.3–1.6) 0.4 (0.4–0.5) 3.8 (3.3–4.3) 10.2 (8.9–11.8) 7.2 (6.9–7.5) 1.6 (1.4–1.9)
Sex
Male 1.4 (1.2–1.6) 0.5 (0.4–0.5) 3.4 (2.8–4.1) 12 (10.0–15.0) 7.9 (7.4–8.4) 1.7 (1.4–2.1)
Female 1.5 (1.3–1.8) 0.4 (0.4–0.4) 3.8 (3.3–4.3) 9.0 (7.4–10.9) 6.7 (6.3–7.1) 1.6 (1.4–1.9)
Severity
Mild/Moderate 1.2 (1.0–1.5) . . .‡ 3.2 (2.6–3.8)§ 9.7 (7.7–12.3) . . .‡ 1.5 (1.3–1.9)§
Severe and UVH 2.2 (1.9–2.7) . . .‡ 6.3 (5.0–7.9)§ 10.6 (7.7–14.5) . . .‡ 1.9 (1.3–2.7)§
Unclassified 1.4 (1.0–1.8) . . .‡ 2.8 (2.0–3.9)§ 10.9 (7.4–16.0) . . .‡ 1.8 (1.2–2.8)§
Birth, y
1910 to 1939 5.1 (3.1–8.5) 0.8 (0.5–1.1) 6.6 (3.4–12.7) 12.4 (10.5–14.8) 9.2 (8.8–9.7) 1.5 (1.2–1.8)
1940 to 1959 2.7 (2.2–3.3) 1.0 (0.9–1.1) 2.9 (2.3–3.6) 7.6 (6.0–9.7) 4.2 (4.6) 1.9 (1.5–2.5)
1960 to 1982 1.2 (1.0–1.4) 0.3 (0.3–0.4) 4.0 (3.3–4.7) . . .k . . .k . . .k
1983 to 1998 0.8 (0.6–1.1) 0.08 (0.05–0.1) 10.8 (6.5–18.0) . . .k . . .k . . .k
Atrial fibrillation 3.6 (2.9–4.4) 0.7 (0.6–0.8) 6.0 (4.5–7.9)§ 12.7 (10.5–15.2) 7.7 (7.2–8.2) 1.8 (1.5–2.3)§
Congestive heart failure 4.2 (3.4–5.2) 0.6 (0.5–0.7) 8.1 (6.0–10.8)§ 12.5 (10.1–15.5) 7.9 (7.4–8.4) 1.8 (1.4–2.3)§
Mechanical heart valve 3.7 (2.5–5.3) 0.4 (0.3–0.6) 6.6 (4.2–10.5)§ 8.2 (3.7–18.2) 5.6 (4.2–7.4) 1.7 (0.7–4.1)§
Older indicates ≥60 years; UVH, univentricular heart; Young, <60 years.
*Per 1000 Person-Years.
†Adjusted for sex and birth year.
‡Not applicable.
§Sex- and birth year-matched controls.
kNo observations.
DOI: 10.1161/JAHA.118.011870 Journal of the American Heart Association 5
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Lanz et al9 examined stroke risk in a Canadian CHD
population. At 64 years of age the cumulative incidence of
ischemic stroke was 6.1% (95% CI: 5.0–7.0) for female CHD
adults and 7.7% (95% CI: 6.4–8.8) for male CHD adults, both
estimates that are similar to our cumulative incidence for CHD
adults at 60 years of age. Mandalenakis et al8 evaluated the
risk of stroke in a relatively young CHD population compared
with a general population comparison cohort. They followed
subjects until a maximum of 42 years of age, at which point
the cumulative incidence of stroke was 1.5% in the CHD
population and 0.2% in the general population. These
incidences equated to an HR of 10.8 for ischemic stroke in
CHD subjects. The higher HR, compared with our results, is
likely owing to a younger age at end of follow-up (42 years
versus 60 years of age for our young category). The study by
Lanz et al9 reported a 30-day mortality of 5.1% for ischemic
stroke, comparable with our finding for CHD adults in the
older category (5%, 95% CI: 3%–8%). When considering both of
these studies relative to our own, it is important to note some
of the differences in study design and study populations. In
particular, Lanz et al9 did not include a comparison cohort,
which precluded the ability to determine the relative risk in
the CHD population. While the study by Mandalenakis et al8
did include a comparison cohort, the study population
represented children and young adults with CHD. Our findings
add to those findings by following the CHD adults into older
ages, when the stroke risk is more substantial in the general
population. In addition, our study adds information about the
ischemic stroke risk relative to measurable clinical factors
such as atrial fibrillation, as well as providing a description of
present day antithrombotic therapy practices.
Heart failure is a well-established risk factor for stroke in
the general population, commonly explained by hemodynamic
changes that potentially lead to thrombus formation.21 In line
with this, we found that the aHR of ischemic stroke in young
CHD adults compared with their sex- and birth year-matched
controls was higher among those with a diagnosis of chronic
heart failure. This finding suggests that chronic heart failure
worsens an already challenging situation. The same applies
for atrial arrhythmias and mechanical heart valves, which are
also well-known stroke risk factors.2,7
Previous attempts to use the CHA2DS2VASc score to
predict thromboembolic risk in CHD patients suffering from
AFib have shown conflicting results.22,23. The different
distribution of age and type of supraventricular arrhythmia
in these studies may to some extent explain this inconsis-
tency. Our study demonstrates an increasing incidence of
ischemic stroke in CHD adults, including those without AFib,
with a CHA2DS2VASc score above 0. While the “CONgenital
COR vitia” study found an association between a CHA2DS2-
VASc score of 2 or above and stroke23, we demonstrate an
increased relative risk of ischemic stroke in CHD adults with a
score of ≥1 (HR=3.1, 95% CI: 2.1–4.5). Further research is
necessary to determine the clinical prospective value of the
CHA2DS2VASc score when evaluating and attempting to
predict the ischemic stroke risk of adults with CHD.
Strengths and Limitations
The main strengths of this study are the large sample size,
duration of follow up, and the limited selection bias afforded
by the nationwide coverage and virtually complete follow-up in
the Danish registries.
The positive predictive value in the DNPR of an overall CHD
diagnosis is 90%.12,24 However, we do not know the positive
Table 3. Incidence Rates of Ischemic Stroke in Congenital Heart Disease Adults According to CHA2DS2VASc Score
CHA2DS2VASc Score
0 1 ≥2 Total
No. of events 210 34 278 522
Rate per 1000 PY (95% CI) 1.0 (0.9–1.2) 5.6 (4.0–7.8) 9.4 (8.3–10.5) 2.2 (2.0–2.3)
Hazard ratio (95% CI) 1 (reference) 3.7 (2.5–5.4) 4.5 (3.6–5.7) . . .
One point for female sex, if in presence of ≥1 of the other covariates. Two points for age ≥75 years and previous thromboembolic disease.
CHA2DS2VASc score indicates one point for congestive heart failure, hypertension, age 65 to 74 years, diabetes mellitus, and vascular disease; PY, person-years.
Figure 2. Thirty-day post-ischemic stroke mortality in congen-
ital heart disease adults and the general population according to
young (<60 years) and older age (≥60 years).
DOI: 10.1161/JAHA.118.011870 Journal of the American Heart Association 6
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predictive value of the specific CHD defects and misclassi-
fication of specific CHD diagnosis, and therefore also CHD
complexity, may be present. Furthermore, in some cases ICD-
codes were insufficiently specific to conclude CHD severity.
The positive predictive value of an ischemic stroke diagnosis
in the DNPR is reportedly between 88% and 97%.25,26 Up to 69%
of “unspecified strokes” are also ischemic strokes.26 The
known positive predictive values of the CHA2DS2VASc-score
covariates in the DNPR are as follows: congestive heart failure
76%,27 arterial hypertension 92%,27 prior transitory ischemic
attack 60% to 68%,25,26 hemorrhagic stroke 66% to 74%,25,26
diabetesmellitus 96%,28 atherosclerosis 69%,29 andmyocardial
infarction 92% to 97%.27
In this study we include descriptive data on the use of
antithrombotic therapy in CHD adults as well as the general
population. We included this data to accommodate criticism
of previous studies.10 However, on the basis of this data our
ability to understand the impact on ischemic stroke risk in the
CHD population is limited. Future studies may investigate how
use of antithrombotic therapy affect the risk of ischemic
stroke in adult CHD patients.
A potential limitation of the study includes the possibility of
surveillance bias given that CHD adults may enter the
healthcare system more frequently relative to the general
population cohort. However, because ischemic stroke is an
acute clinical diagnosis, which often appears spontaneously
without warning symptoms, there is less likelihood that
frequent visits to the doctor will affect the detection of
ischemic stroke compared with other acquired conditions. We
therefore do not believe that surveillance bias can explain the
observed difference in ischemic stroke risk.
We classified simple CHD as patients who had not
undergone cardiac surgery. However, because our data
spread across several decades some patients may not have
received operation because they were deemed inoperable at
the time, causing us to include some potentially high-risk
individuals in our simple CHD category.
We included adults in the CHD cohort at the time of CHD
diagnosis. Thus, ischemic strokes could potentially for some
individuals be left-censored before 1977. Patients born before
1977 who also had a stroke before 1977, may represent high-
risk individuals which may cause us to overestimate the
association between CHD and ischemic stroke in the early
birth categories. However, to the extent that CHD adults
experiencing a fatal ischemic stroke before 1977, estimates
of the association between CHD and ischemic stroke are
conservative. Importantly, this limitation did not pertain to the
analyses on subgroups born after 1977.
We assessed post-stroke mortality as all-cause mortality
within 30 days of an ischemic stroke. Our data do not allow
us to seek out the exact cause of death but given the short
window of time between ischemic stroke event and death
allows us to infer that a substantial number of deaths within
30 days of stroke will be stroke related.
We considered cardiovascular disease as an intermediate
step in a potential causal pathway between CHD and ischemic
stroke. As such, to avoid underestimation of any potential
association between CHD and ischemic stroke, no cardiovas-
cular diseases were included in the regression model as
potential confounders. Documentation of stroke-associated
lifestyle factors such as overweight/obesity, smoking habit,
and alcohol consumption is generally lacking in our
databases. In addition, complete data on the degree and
duration of cyanosis were not available. Lastly, we are limited
to addressing only clinically significant embolic events.30
Conclusions
Adults with CHD have an increased relative risk of ischemic
stroke and stroke-associated mortality compared with the
general population. This relative risk was particularly high in
younger groups aged <60 years, as well as those with
traditional stroke risk factors such as heart failure, arrhyth-
mia, and a history of mechanical heart valve replacement. This
was despite indications of a high prevalence of anticoagula-
tion therapy use. The impact of traditional stroke risk factors,
as measured by the CHA2DS2VASc score, seem to be
substantial in the adult CHD population. Future studies may
include a prospective application of the CHA2DS2VASc score
to the population of adult CHD patients or potentially
Table 4. Proportions of Individuals, Living in Denmark on December 31, 2016, Filling in Prescriptions of Antithrombotic Therapy
during 2015–2016
Proportion, % (95% CI)
Congenital Heart Disease Cohort (n=14 856) General Population Comparison Cohort (n=157 505)
Antithrombotic therapy 1 to 4 prescriptions ≥5 prescriptions 1 to 4 prescriptions ≥5 prescriptions
Vitamin K antagonist 1% (1.0–2.0) 7% (6.9–7.7) 0.2% (0.2–0.2) 0.8% (0.7–0.8)
Non-vitamin K antagonist 1% (1.0–1.4) 2% (1.3–2.0) 0.4% (0.4–0.4) 0.5% (0.5–0.6)
Platelet aggregation inhibitors 4% (3.4–4.1) 5% (4.6–5.3) 2% (1.8–1.9) 3% (3.2–3.4)
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development of a new stroke risk prediction model to predict
high-risk CHD individuals for ischemic stroke.
Sources of Funding
This study was financially supported by grants from The Heart
Institute, Cincinnati Children’s Hospital Medical Center;
Department of Clinical Epidemiology, Aarhus University
Hospital, Denmark; A.P Moeller Foundation, Copenhagen,
Denmark, and Familien Hede Nielsens Foundation, Horsens,




1. Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M.
Lifetime prevalence of congenital heart disease in the general population from
2000 to 2010. Circulation. 2014;130:749–756.
2. Bouchardy J, Therrien J, Pilote L, Ionescu-Ittu R, Martucci G, Bottega N, Marelli
AJ. Atrial arrhythmias in adults with congenital heart disease. Circulation.
2009;120:1679–1686.
3. Fahed AC, Roberts AE, Mital S, Lakdawala NK. Heart failure in congenital heart
disease: a confluence of acquired and congenital. Heart Fail Clin.
2014;10:219–227.
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor
for stroke: the Framingham Study. Stroke. 1991;22:983–988.
5. Hays AG, Sacco RL, Rundek T, Sciacca RR, Jin Z, Liu R, Homma S, Di Tullio MR.
Left ventricular systolic dysfunction and the risk of ischemic stroke in a
multiethnic population. Stroke. 2006;37:1715–1719.
6. Chun DS, Schamberger MS, Flaspohler T, Turrentine MW, Brown JW, Farrell AG,
Girod DA. Incidence, outcome, and risk factors for stroke after the Fontan
procedure. Am J Cardiol. 2004;93:117–119.
7. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding
complications in patients with mechanical heart valve prostheses. Circulation.
1994;89:635–641.
8. Mandalenakis Z, Rosengren A, Lappas G, Eriksson P, Hansson PO, Dellborg M.
Ischemic Stroke in Children and Young Adults With Congenital Heart Disease. J
Am Heart Assoc. 2016;5:e003071. DOI: 10.1161/JAHA.115.003071.
9. Lanz J, Brophy JM, Therrien J, Kaouache M, Guo L, Marelli AJ. Stroke in adults
with congenital heart disease: incidence, cumulative risk, and predictors.
Circulation. 2015;132:2385–2394.
10. Opotowsky AR, Webb GD. Population-based data on congenital heart disease
and stroke. J Am Heart Assoc. 2016;5:e003257. DOI: 10.1161/JAHA.116.
003257.
11. Schmidt MPL, Sørensen HT. The Danish civil registration system as a tool in
epidemiology. Eur J Epidemiol. 2014;29:541–549.
12. Olsen M, Videbaek J, Johnsen SP; Danish Register of Congenital Heart D. The
Danish Register of congenital heart disease. Scand J Public Health.
2011;39:50–53.
13. Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen
HT. The Danish National Patient Registry: a review of content, data quality, and
research potential. Clin Epidemiol. 2015;7:449–490.
14. Videbæk J, Laursen HB, Olsen M, Høfsten DE, Johnsen SP. Long-term
nationwide follow-up study of simple congenital heart disease diagnosed in
otherwise healthy children. Circulation. 2016;133:474–483.
15. Jost CHA, Connolly HM, Scott CG, Burkhart HM, Ammash NM, Dearani JA.
Increased risk of possible paradoxical embolic events in adults with ebstein
anomaly and severe tricuspid regurgitation. Congenit Heart Dis. 2014;9:30–37.
16. Madsen NL, Marino BS, Woo JG, Thomsen RW, Videboek J, Laursen HB, Olsen
M. Congenital heart disease with and without cyanotic potential and the long-
term risk of diabetes mellitus. A population-based follow-up study. J Am Heart
Assoc. 2016;5:e003076. DOI: 10.1161/JAHA.115.003076.
17. Pottegard A, Schmidt SAJ, Wallach-Kildemoes H, Sorensen HT, Hallas J,
Schmidt M. Data resource profile: the Danish National Prescription Registry.
Int J Epidemiol. 2017;46:798–798f.
18. Friberg L, Rosenqvist MLip GY. Evaluation of risk stratification schemes for
ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the
Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33:1500–1510.
19. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer
C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C. Validation of risk
stratification schemes for predicting stroke and thromboembolism in patients
with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.
20. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a
competing risk. J Am Stat Assoc. 1999;94:496–509.
21. Haeusler KG, Laufs U, Endres M. Chronic heart failure and ischemic stroke.
Stroke. 2011;42:2977–2982.
22. Khairy P, Aboulhosn J, Broberg CS, Cohen S, Cook S, Dore A, Fernandes SM,
Fournier A, Kay J, Levesque S, Macle L, Marcotte F, Mondesert B, Mongeon FP,
Opotowsky AR, Proietti A, Rivard L, Ting J, Thibault B, Zaidi A, Hamilton R;
Anticoagulation Therapy in Congenital Heart Disease (TACTIC) investigators
and the Alliance for Adult Research in Congenital Cardiology (AARCC).
Thromboprophylaxis for atrial arrhythmias in congenital heart disease: a
multicenter study. Int J Cardiol. 2016;223:729–735.
23. Heidendael JF, Bokma JP, de Groot JR, Koolbergen DR, Mulder BJ, Bouma
BJ. Weighing the risks: thrombotic and bleeding events in adults with
atrial arrhythmias and congenital heart disease. Int J Cardiol. 2015;186:
315–320.
24. Agergaard P, Hebert A, Bjerre J, Sorensen KM, Olesen C, Ostergaard JR.
Children diagnosed with congenital cardiac malformations at the national
university departments of pediatric cardiology: positive predictive values of
data in the Danish National Patient Registry. Clin Epidemiol. 2011;3:61–66.
25. Krarup LH, Boysen G, Janjua H, Prescott E, Truelsen T. Validity of stroke diagnoses
in a National Register of Patients. Neuroepidemiology. 2007;28:150–154.
26. Johnsen SP, Overvad K, Sorensen HT, Tjonneland A, Husted SE. Predictive
value of stroke and transient ischemic attack discharge diagnoses in the
Danish National Registry of Patients. J Clin Epidemiol. 2002;55:602–607.
27. Sundboll J, Adelborg K, Munch T, Froslev T, Sorensen HT, Botker HE, Schmidt
M. Positive predictive value of cardiovascular diagnoses in the Danish National
Patient Registry: a validation study. BMJ Open. 2016;6:e012832.
28. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT. The
predictive value of ICD-10 diagnostic coding used to assess Charlson
comorbidity index conditions in the population-based Danish National Registry
of Patients. BMC Med Res Methodol. 2011;11:83.
29. Lasota AN, Overvad K, Eriksen HH, Tjonneland A, Schmidt EB, Gronholdt MM.
Validity of peripheral arterial disease diagnoses in the Danish National Patient
Registry. Eur J Vasc Endovasc Surg. 2017;53:679–685.
30. Jensen AS, Idorn L, Thomsen C, von der Recke P, Mortensen J, Sorensen KE,
Thilen U, Nagy E, Kofoed KF, Ostrowski SR, Sondergaard L. Prevalence of
cerebral and pulmonary thrombosis in patients with cyanotic congenital heart
disease. Heart. 2015;101:1540–1546.
DOI: 10.1161/JAHA.118.011870 Journal of the American Heart Association 8



























 http://ahajournals.org by on July 26, 2019
Table S1. Diagnostic and procedure codes. 
 
 
 ICD-8 ICD-10 
CHD 746-747, except 746.99, 747.59, 
747.69, 747.89, 747.99 
Q20-Q26, except Q20.9, 
Q21.9, Q23.1A, Q24.6, 
Q24.9, Q25.9, Q26.1, Q26.5, 
Q26.6, Q26.9, Q27  
Ischemic stroke  433, 434 I63, I64 
Congestive heart failure  42709, 42710, 42711, 42719, 
42899, 78249 
I500, I501, I502, I503, I508, 
I509, I110, I130, I132, I420, 
I426, I427, I428, I429 
Hypertension  400, 401, 402, 403, 404 I10, I11, I12, I13, I15 
Diabetes mellitus  249.00, 249.06, 249.07, 249.09, 
250.00, 250.06, 250.07, 250.09 
E10, E11, E12, E13, E14, 
G632, H360, N083 
Systemic embolism  444.0, 444.1, 444.2, 444.3, 
444.4, 444.9 
I74, K550, N280 
Transitory ischemic 
attack  
435.09, 435.99 G450, G451, G452, G458, 
G459 
Hemorrhagic stroke  431 I61 
Peripheral vascular 
disease  
440, 443.99 I70, I739 
Myocardial infarction  410 I21, I22 
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